MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1161/circulationaha.118.038169

Медицинская библиотека · Circulation · 2019

Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.

Lane Thirusha, Fontana Marianna, Martinez-Naharro Ana, Quarta Candida Cristina, Whelan Carol J, Petrie Aviva, Rowczenio Dorota M, Gilbertson Janet A, Hutt David F, Rezk Tamer, Strehina Svetla G, Caringal-Galima Joan, Manwani Richa, Sharpley Faye A, Wechalekar Ashutosh D, Lachmann Helen J, Mahmood Shameem, Sachchithanantham Sajitha, Drage Edmund P S, Jenner Harvey D, McDonald Rosie, Bertolli Ottavia, Calleja Alan, Hawkins Philip N, Gillmore Julian D

СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure in older individuals. We sought to characterize the natural history of ATTR-CM and compare outcomes and quality of life among patients with acquired and hereditary forms of the disease.

METHODS

We studied 711 patients with wild-type ATTR-CM, 205 with hereditary ATTR-CM associated with the V1221 variant (V122I-hATTR-CM), and 118 with non-V122I-hATTR-CM at the UK National Amyloidosis Center between 2000 and 2017. Patients underwent prospective protocolized evaluations comprising assessment of cardiac parameters, functional status by 6-minute walk test, quality of life according to the Kansas City Cardiomyopathy Questionnaire, and survival. Hospital service usage pre- and postdiagnosis was established using English central health records in a subset of patients.

RESULTS

There was substantial diagnostic delay, with patients using hospital services a median (interquartile range) of 17 (9-27) times during the 3 years before diagnosis, by which time quality of life was poor; diagnosis of wild-type ATTR-CM was delayed >4 years after presentation with cardiac symptoms in 42% of cases. Patients with V122I-hATTR-CM were more impaired functionally ( P<0.001) and had worse measures of cardiac disease ( P<0.001) at the time of diagnosis, a greater decline in quality of life, and poorer survival ( P<0.001) in comparison with the other subgroups.

CONCLUSIONS

ATTR-CM is an inexorably progressive and eventually fatal cardiomyopathy associated with poor quality of life. Diagnosis is often delayed for many years after symptoms develop. Improved awareness and wider use of recently validated diagnostic imaging methods are urgently required for patients to benefit from recent therapeutic developments.

Для цитирования: Lane Thirusha, Fontana Marianna, Martinez-Naharro Ana, Quarta Candida Cristina, Whelan Carol J, Petrie Aviva, Rowczenio Dorota M, Gilbertson Janet A, Hutt David F, Rezk Tamer, Strehina Svetla G, Caringal-Galima Joan, Manwani Richa, Sharpley Faye A, Wechalekar Ashutosh D, Lachmann Helen J, Mahmood Shameem, Sachchithanantham Sajitha, Drage Edmund P S, Jenner Harvey D, McDonald Rosie, Bertolli Ottavia, Calleja Alan, Hawkins Philip N, Gillmore Julian D. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.. Circulation. 2019. DOI: 10.1161/circulationaha.118.038169.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.